Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

285
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
285
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

45
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
45
Quality Assurance01:19

Quality Assurance

3.9K
Quality assurance is the overarching term used to describe the activities employed to ensure the proper performance of a system. These activities can be classified into three categories: quality control, quality assessment, and internal corrective measures. Typically, these activities work cyclically: quality control is performed before and during the analysis, while quality assessment occurs during and after the investigation. Internal corrective measures are implemented based on the findings...
3.9K
Testing Water Quality01:14

Testing Water Quality

564
When the quality of water for concrete preparation is uncertain, its impact on the setting time of cement and compressive strength of mortar is assessed by comparison with de-ionized or distilled water benchmarks. American Society for Testing and Materials (ASTM) C1602 requires the setting times to be within 90 minutes of the control, British Standard (BS) 3146:1980 allows a 30-minute variance in the initial setting, while British Standards European Norm (BS EN) 1008 specifies initial setting...
564
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

246
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
246
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

330
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
330

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Corrigendum to "Nonclinical cardiovascular safety assessment of thioridazine: Impact of heart rate, body temperature, and choice of species" [Journal of Pharmacological and Toxicological Methods, Volume 115 (2022), 107167].

Journal of pharmacological and toxicological methods·2026
Same author

Internodal conduction pathways: revisiting a century-long debate on their existence, morphology, and location in the context of 2023 best science.

Advances in physiology education·2023
Same author

Remembering the canonical discoverers of the core components of the mammalian cardiac conduction system: Keith and Flack, Aschoff and Tawara, His, and Purkinje.

Advances in physiology education·2022
Same author

Nonclinical cardiovascular safety assessment of thioridazine: Impact of autonomic tone, body temperature, and choice of species.

Journal of pharmacological and toxicological methods·2022
Same author

19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).

Expert opinion on drug safety·2020
Same author

18<sup>th</sup> Annual Meeting of the Safety Pharmacology Society: drug safety assessment on gastrointestinal system functions.

Expert opinion on drug safety·2019

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K

CiPA: Ongoing testing, future qualification procedures, and pending issues.

Icilio Cavero1, Henry Holzgrefe2

  • 154 Rue de la Glacière, 75013 Paris, France.

Journal of Pharmacological and Toxicological Methods
|July 11, 2015
PubMed
Summary

The Comprehensive In Vitro Proarrhythmia Assay (CiPA) assesses drug safety by examining cardiac ion channel effects, computational models, and human stem cell-derived cardiomyocytes. This mechanism-based approach aids in identifying potential drug-induced heart rhythm problems.

Keywords:
Cardiac action potentialCardiac ion channel assaysCiPACiPA working groupsComprehensive in vitro proarrhythmia assayHuman stem cell-derived cardiomyocytesMEASafety PharmacologyVSOhSC-CMs

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.6K
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

1.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.6K
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

1.4K

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Safety Assessment

Background:

  • The Comprehensive In Vitro Proarrhythmia Assay (CiPA) is a novel, mechanism-based approach for evaluating drug-induced proarrhythmic liability.
  • Traditional methods for assessing drug proarrhythmia have limitations, necessitating the development of more predictive assays.

Purpose of the Study:

  • To outline the multi-step CiPA paradigm for comprehensive drug proarrhythmia risk assessment.
  • To detail the methodologies and validation strategies employed within the CiPA framework.

Main Methods:

  • CiPA involves three key stages: assessing effects on cloned human cardiac ion channels, evaluating proarrhythmic markers using a computational ventricular action potential model, and analyzing effects in human stem cell-derived cardiomyocytes (hSC-CMs).
  • Standardized protocols for patch clamp electrophysiology, in silico modeling (modified O'Hara-Rudy), and hSC-CM measurements (MEA and VSD) have been established.
  • A set of 29 reference drugs are utilized for testing and validating the CiPA assay.

Main Results:

  • The proposed CiPA protocols and models provide a structured framework for evaluating drug effects on cardiac electrophysiology.
  • Validation using reference drugs aims to establish the reliability and predictivity of the CiPA assay in identifying proarrhythmic risks.

Conclusions:

  • The adoption of CiPA as a drug development tool requires significant effort due to its complex, multi-faceted nature.
  • Successful implementation of CiPA will enhance the identification of electrophysiological mechanisms underlying drug-induced proarrhythmia, improving candidate drug safety.